Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

62462 1502285060HCLSReviewMexicoJuly2017.pdf
Energy Boardroom

Type your email in the box below to read this content NOW:

Interview

Ko-Chung Lin PhD – Founder & CEO, PharmaEssentia, Taiwan

1Ko-Chung Lin, founder and CEO of PharmaEssentia, documents the main specificities of the company’s groundbreaking ropeginterferon alfa-2b, a once-every-two-week interferon displaying a unique toxicity profile. In this regard, Mr. Lin also provides insights into PharmaEssentia’s approach to the upcoming launch of this product into the US market as well as his vision for the international development of the company, which already stands as one of the most advanced and ambitious biopharmaceutical companies headquartered in Taiwan.

LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: